Jiamin Cao

发表

The miR-103a-3p/TGFBR3 axis regulates TGF-β-induced orbital fibroblast activation and fibrosis in thyroid-eye disease

Feng Zhang, Yizhi Chen, Wei Xiong, 2022, Molecular and Cellular Endocrinology.

The risk factors for Graves’ ophthalmopathy

Chen Ma, W. Xiong, Yuhe Su, 2021, Graefe's Archive for Clinical and Experimental Ophthalmology.

RNA aptamers with specific binding affinity to CD40 (CD40Apt) represents a promising antagonist of the CD40-CD40L signaling for thyroid-associated ophthalmopathy (TAO) treatment in mouse

Yizhi Chen, Feng Zhang, Renhong Tang, 2023, Journal of Translational Medicine.

Gentiopicroside inhibits retinoblastoma cell proliferation, invasion, and tumorigenesis in nude mice by suppressing the PI3K/AKT pathway.

Jiayang Yin, Feng Zhang, W. Xiong, 2023, Naunyn-Schmiedeberg's archives of pharmacology.

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology

W. Xiong, Feng Zhang, Jiamin Cao, 2023, International journal of nanomedicine.

A cause–effect relationship between Graves’ disease and the gut microbiome contributes to the thyroid–gut axis: A bidirectional two-sample Mendelian randomization study

Yongde Luo, X. Qi, W. Xiong, 2023, Frontiers in Immunology.

A TSHR-Targeting Aptamer in Monocytes Correlating with Clinical Activity in TAO

W. Xiong, Jiamin Cao, Changci Chenzhao, 2024, International journal of nanomedicine.

Interactive Journal of Medical Research

Zuopeng Zhang, ZanFeng Cao, Fangge Deng, 2022 .

Elucidating the role of genetically determined metabolites in Diabetic Retinopathy: insights from a mendelian randomization analysis.

W. Xiong, Jiamin Cao, Bingyu Xie, 2024, Acta diabetologica.

Genetically Determined Metabolites in Graves Disease: Insight From a Mendelian Randomization Study

W. Xiong, Jiamin Cao, Bingyu Xie, 2023, Journal of the Endocrine Society.